VPS35 (Q96QK1) variants and mutations
VPS35 (also known as Q96QK1) is a human protein-coding gene encoding a vacuolar protein sorting-associated protein 35 protein. It helps retromer complexes retrieve selected cargo from endosomes for recycling to the Golgi or cell surface instead of lysosomal degradation. The p.Asp620Asn variant causes autosomal dominant Parkinson disease and links impaired endosomal trafficking to neurodegeneration. This analysis covers 846 VPS35 variants and mutations. Of these, 75% have computational variant effect predictions. Disease context includes Hereditary late-onset Parkinson disease, neurodegenerative disease, and Young adult-onset Parkinsonism. Example VPS35 variants include T3A, T4A, and Q5*.
Variant analysis overview
- Gene: VPS35
- Protein: Q96QK1
- UniProt accession: Q96QK1
- Organism: Homo sapiens
- Variants analyzed: 846
- Variant scope: all variants
- Completed: 2026-08-18
Variant and mutation evidence
- Variant composition: 595 unspecified-consequence records; 1 stop retained variant; 125 missense variants; 5 frameshift variants; 109 synonymous variants; 3 stop-gained variants; 3 splice-region variants; 2 in-frame deletions; 2 in-frame insertions; 1 substitution
- Prediction scores: 635 variants have prediction scores (75% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Hereditary late-onset Parkinson disease, neurodegenerative disease, Young adult-onset Parkinsonism, Parkinson disease, late-onset Parkinson disease, Parkinson disease, dominant, hereditary disease, lysosomal storage disease, neoplasm, hepatocellular carcinoma, gastric cancer, Alzheimer disease.
Protein structure and variant hotspots
- Protein features: 3 post-translational modification sites.
- PTM context: 1 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable VPS35 variants
Examples include T3A, T4A, Q5*, Q6H, P8L, D10N, E11Q, E13K. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- T3A (p.Thr3Ala), ExAC rs774604183, gnomAD rs774604183, REVEL 0.11, CADD 22.20
- T4A (p.Thr4Ala), Ensembl rs1966266744, REVEL 0.12, CADD 23.90
- Q5* (p.Gln5Ter), rs2143009092, ClinGen CA395816150, ClinVar RCV001358877, Ensembl rs2143009092, Uncertain significance
- Q6H (p.Gln6His), TOPMed rs1966266705
- P8L (p.Pro8Leu), TOPMed rs1187804419, REVEL 0.25, CADD 25.30
- D10N (p.Asp10Asn), Ensembl rs2143009089
- E11Q (p.Glu11Gln), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E13K (p.Glu13Lys), Ensembl rs1966266286
- K14N (p.Lys14Asn), NCI-TCGA Cosmic COSV5448, cosmic curated COSV54480, REVEL 0.26, CADD 23.80, Variant assessed as somatic; moderate impact.
- D17G (p.Asp17Gly), NCI-TCGA Cosmic COSV1001, cosmic curated COSV10014, REVEL 0.32, CADD 24.30, Variant assessed as somatic; moderate impact.
- D17V (p.Asp17Val), ExAC rs773381942, TOPMed rs773381942, gnomAD rs773381942, REVEL 0.53, CADD 31.00, Uncertain significance, Inborn genetic diseases
- A19G (p.Ala19Gly), ESP rs370411054, ExAC rs370411054, TOPMed rs370411054, gnomAD rs370411054, REVEL 0.30, CADD 27.50
- I20M (p.Ile20Met), ExAC rs781646463, gnomAD rs781646463, REVEL 0.15, CADD 15.20
- Q21P (p.Gln21Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Q21R (p.Gln21Arg), TOPMed rs1192520905, gnomAD rs1192520905, REVEL 0.23, CADD 21.70
- A22G (p.Ala22Gly), gnomAD rs1254449170, REVEL 0.17, CADD 25.10
- A22S (p.Ala22Ser), ExAC rs769187894, TOPMed rs769187894, gnomAD rs769187894, REVEL 0.12, CADD 22.40
- A22T (p.Ala22Thr), ExAC rs769187894, TOPMed rs769187894, gnomAD rs769187894, REVEL 0.14, CADD 22.40, Uncertain significance, Inborn genetic diseases
- V23G (p.Val23Gly), Ensembl rs996986541, REVEL 0.84, CADD 29.70
- K24E (p.Lys24Glu), Ensembl rs899986090
- V25G (p.Val25Gly), Ensembl rs1596725468
- S27A (p.Ser27Ala), ExAC rs745338373, gnomAD rs745338373
- S27L (p.Ser27Leu), TOPMed rs1338443223, gnomAD rs1338443223, REVEL 0.39, CADD 24.00
- M30K (p.Met30Lys), rs145147781, ClinGen CA8037124, ClinVar RCV000406026, ClinVar RCV005865298, REVEL 0.83, CADD 28.70, Uncertain significance, not provided; Parkinson disease 17
- R32I (p.Arg32Ile), Ensembl rs1596725451
- D35H (p.Asp35His), gnomAD rs1342046894, REVEL 0.63, CADD 33.00
- K36E (p.Lys36Glu), rs2548885790, ClinGen CA395815493, ClinVar RCV003007608, Uncertain significance, Parkinson disease 17
- K36I (p.Lys36Ile), Ensembl rs1596724546
- N37S (p.Asn37Ser), rs777006799, ClinGen CA8037108, ClinVar RCV001983502, ClinVar RCV004793678, REVEL 0.05, CADD 20.60, Uncertain significance, Parkinson disease 17; not provided
- N37T (p.Asn37Thr), ExAC rs777006799, TOPMed rs777006799, gnomAD rs777006799, REVEL 0.12, CADD 23.30, Uncertain significance
- H45Y (p.His45Tyr), TOPMed rs1448750143, gnomAD rs1448750143, REVEL 0.36, CADD 22.70
- A46V (p.Ala46Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- M49I (p.Met49Ile), TOPMed rs1966245031, gnomAD rs1966245031, REVEL 0.32, CADD 23.70
- G51S (p.Gly51Ser), rs193077277, ClinGen CA8037106, ClinVar RCV000577720, ClinVar RCV002225671, REVEL 0.24, CADD 21.70, Conflicting interpretations, not provided; Parkinson disease 17
- R54Q (p.Arg54Gln), ExAC rs770464667, TOPMed rs770464667, gnomAD rs770464667, REVEL 0.61, CADD 28.20, Uncertain significance, Parkinson disease 17
- R54W (p.Arg54Trp), rs186122975, 1000Genomes rs186122975, ESP rs186122975, ExAC rs186122975, REVEL 0.70, CADD 29.30, Variant assessed as somatic; moderate impact.
- T55A (p.Thr55Ala), gnomAD rs1156343828, REVEL 0.57, CADD 27.40
- S56C (p.Ser56Cys), Ensembl rs2143008890
- S56F (p.Ser56Phe), NCI-TCGA Cosmic COSV1001, NCI-TCGA Cosmic COSV5447, Variant assessed as somatic; moderate impact.
- S56P (p.Ser56Pro), gnomAD rs1469288470, REVEL 0.56, CADD 24.80
- M57I (p.Met57Ile), rs183554824, ClinGen CA280221262, ClinVar RCV000577231, ClinVar RCV002225672, REVEL 0.19, CADD 20.20, Conflicting interpretations, not provided; Parkinson disease 17
- M57L (p.Met57Leu), ESP rs375285388, ExAC rs375285388, TOPMed rs375285388, gnomAD rs375285388, REVEL 0.39, CADD 21.10, Uncertain significance
- M57V (p.Met57Val), ESP rs375285388, ExAC rs375285388, TOPMed rs375285388, gnomAD rs375285388, REVEL 0.23, CADD 17.30, Uncertain significance, Inborn genetic diseases
- K61N (p.Lys61Asn), NCI-TCGA Cosmic COSV5448, Variant assessed as somatic; moderate impact.
- S62R (p.Ser62Arg), gnomAD rs1256556517, REVEL 0.30, CADD 23.00
- E65G (p.Glu65Gly), Ensembl rs11550464
- E65V (p.Glu65Val), Ensembl rs11550464
- Y67H (p.Tyr67His), gnomAD rs1211485116, REVEL 0.80, CADD 28.40
- M68I (p.Met68Ile), rs1131691531, ClinGen CA395815020, ClinVar RCV000493157, Ensembl rs1131691531, AlphaMissense 0.96, MetaLR 0.17, Uncertain significance, not provided
- A69D (p.Ala69Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- A69P (p.Ala69Pro), NCI-TCGA Cosmic COSV1001, Variant assessed as somatic; moderate impact.
- A69T (p.Ala69Thr), gnomAD rs1966235127, REVEL 0.18, CADD 23.20
- I70F (p.Ile70Phe), ExAC rs781057884, TOPMed rs781057884, gnomAD rs781057884, REVEL 0.49, CADD 26.20
- I70V (p.Ile70Val), ExAC rs781057884, TOPMed rs781057884, gnomAD rs781057884
- S71F (p.Ser71Phe), rs754806601, NCI-TCGA Cosmic COSV5447, ExAC rs754806601, gnomAD rs754806601, REVEL 0.44, CADD 24.20, Variant assessed as somatic; moderate impact.
- H75P (p.His75Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- H75Q (p.His75Gln), 1000Genomes rs529522862, ExAC rs529522862, gnomAD rs529522862, REVEL 0.15, CADD 20.30
- H75R (p.His75Arg), ExAC rs746848785, gnomAD rs746848785, REVEL 0.32, CADD 19.20
- Y76C (p.Tyr76Cys), ExAC rs758294660, TOPMed rs758294660, gnomAD rs758294660, REVEL 0.34, CADD 23.50
- Y76H (p.Tyr76His), TOPMed rs888688416, gnomAD rs888688416, REVEL 0.25, CADD 21.30
- L77S (p.Leu77Ser), Ensembl rs11550462
- Y80C (p.Tyr80Cys), gnomAD rs1375727764, REVEL 0.69, CADD 29.10
- T82R (p.Thr82Arg), rs188245364, UniProt VAR 066655, Ensembl rs188245364, REVEL 0.31, CADD 22.60
- D83E (p.Asp83Glu), Ensembl rs12920740, REVEL 0.11, CADD 15.40
- D83V (p.Asp83Val), Ensembl rs12925313
- R89K (p.Arg89Lys), ExAC rs750463506, gnomAD rs750463506, REVEL 0.17, CADD 22.30
- R89W (p.Arg89Trp), rs2548885319, ClinGen CA395814745, ClinVar RCV003901981, ClinVar RCV005301414, REVEL 0.39, CADD 29.20, Uncertain significance, Inborn genetic diseases
- A92S (p.Ala92Ser), TOPMed rs1326491017, gnomAD rs1326491017, REVEL 0.15, CADD 22.10
- D93Y (p.Asp93Tyr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L94F (p.Leu94Phe), NCI-TCGA Cosmic COSV1001, Variant assessed as somatic; moderate impact.
- E96K (p.Glu96Lys), NCI-TCGA Cosmic COSV5447, Ensembl rs1596723981, Variant assessed as somatic; moderate impact.
- G102A (p.Gly102Ala), NCI-TCGA Cosmic COSV5447, REVEL 0.54, CADD 26.50, Variant assessed as somatic; moderate impact.
- N103F (p.Asn103Phe), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- I105M (p.Ile105Met), ExAC rs764351948, TOPMed rs764351948, gnomAD rs764351948
- P106A (p.Pro106Ala), NCI-TCGA Cosmic COSV1001, Variant assessed as somatic; moderate impact.
- P106Q (p.Pro106Gln), TOPMed rs1966233247
- Y109C (p.Tyr109Cys), Ensembl rs1966223750
- T113I (p.Thr113Ile), gnomAD rs1352539649, REVEL 0.68, CADD 28.60
- V114I (p.Val114Ile), rs2548884932, ClinGen CA395814492, ClinVar RCV002820969, Uncertain significance, Parkinson disease 17
- V117I (p.Val117Ile), TOPMed rs1966223542
- F122Y (p.Phe122Tyr), TOPMed rs1966223321
- P123L (p.Pro123Leu), TOPMed rs1421508866, gnomAD rs1421508866, REVEL 0.13, CADD 22.50
- P123R (p.Pro123Arg), TOPMed rs1421508866, gnomAD rs1421508866, REVEL 0.13, CADD 22.10
- S125C (p.Ser125Cys), NCI-TCGA Cosmic COSV5447, Variant assessed as somatic; moderate impact.
- S125Y (p.Ser125Tyr), NCI-TCGA Cosmic COSV5447, Variant assessed as somatic; moderate impact.
- R126S (p.Arg126Ser), ESP rs141444850, ExAC rs141444850, TOPMed rs141444850, gnomAD rs141444850, REVEL 0.27, CADD 22.20
- K127N (p.Lys127Asn), NCI-TCGA Cosmic COSV1001, Variant assessed as somatic; moderate impact.
- K127R (p.Lys127Arg), TOPMed rs1355860794, gnomAD rs1355860794, REVEL 0.12, CADD 22.60, Uncertain significance, Inborn genetic diseases
- D128N (p.Asp128Asn), ESP rs375986040, ExAC rs375986040, TOPMed rs375986040, gnomAD rs375986040, REVEL 0.32, CADD 24.30
- D128Y (p.Asp128Tyr), NCI-TCGA Cosmic COSV1001, Variant assessed as somatic; moderate impact.
- D132Y (p.Asp132Tyr), NCI-TCGA Cosmic COSV1001, Variant assessed as somatic; moderate impact.
- E135K (p.Glu135Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R138C (p.Arg138Cys), NCI-TCGA TCGA novel, REVEL 0.70, CADD 31.00, Variant assessed as somatic; moderate impact.
- R138H (p.Arg138His), rs2548884889, ClinGen CA395814320, ClinVar RCV004482808, ClinVar RCV006484126, REVEL 0.61, CADD 27.20, Uncertain significance, Inborn genetic diseases; Parkinson disease 17
- H142N (p.His142Asn), TOPMed rs1966222581, gnomAD rs1966222581, REVEL 0.50, CADD 27.10
- R145M (p.Arg145Met), NCI-TCGA Cosmic COSV1001, NCI-TCGA Cosmic COSV5448, Variant assessed as somatic; moderate impact.
- G146C (p.Gly146Cys), gnomAD rs1438790266, REVEL 0.91, CADD 27.20
- R150Q (p.Arg150Gln), NCI-TCGA Cosmic COSV5448, Variant assessed as somatic; moderate impact.
- N151S (p.Asn151Ser), gnomAD rs1208923463, REVEL 0.19, CADD 22.60
- Q155R (p.Gln155Arg), TOPMed rs1483697699, gnomAD rs1483697699, REVEL 0.66, CADD 24.40
- C156R (p.Cys156Arg), ExAC rs778970704, gnomAD rs778970704, REVEL 0.61, CADD 24.50
- I160T (p.Ile160Thr), TOPMed rs1370792454, gnomAD rs1370792454, REVEL 0.22, CADD 22.60, Uncertain significance, Inborn genetic diseases
- P162T (p.Pro162Thr), ExAC rs777932822, gnomAD rs777932822, REVEL 0.89, CADD 26.00
- E164G (p.Glu164Gly), Ensembl rs1966221761
- E166K (p.Glu166Lys), ExAC rs756353898, gnomAD rs756353898, REVEL 0.25, CADD 23.10
- P167Q (p.Pro167Gln), ExAC rs753047950, gnomAD rs753047950, REVEL 0.07, CADD 21.10
- P167S (p.Pro167Ser), NCI-TCGA Cosmic COSV1001, REVEL 0.10, CADD 20.80, Variant assessed as somatic; moderate impact.
- D169H (p.Asp169His), rs1434089382, ClinGen CA395813951, ClinVar RCV001117354, gnomAD rs1434089382, REVEL 0.11, CADD 23.90, Uncertain significance, Parkinson disease 17
- E170G (p.Glu170Gly), TOPMed rs1966194476, REVEL 0.20, CADD 23.30
- E170K (p.Glu170Lys), gnomAD rs1401575639, REVEL 0.13, CADD 24.40
- E171* (p.Glu171Ter), NCI-TCGA Cosmic COSV5448, Variant assessed as somatic; high impact.
- E171D (p.Glu171Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T172A (p.Thr172Ala), TOPMed rs1966194381, Uncertain significance, Parkinson disease 17
- T173I (p.Thr173Ile), Ensembl rs866669881, REVEL 0.33, CADD 23.30
- S177N (p.Ser177Asn), gnomAD rs1186313084, REVEL 0.15, CADD 16.80
- S179A (p.Ser179Ala), Ensembl rs1966194182
- M180V (p.Met180Val), TOPMed rs1966194020, REVEL 0.10, CADD 21.40
- A188E (p.Ala188Glu), 1000Genomes rs200388382
- R196* (p.Arg196Ter), 1000Genomes rs201098565, ExAC rs201098565, gnomAD rs201098565, CADD 36.00
- R196Q (p.Arg196Gln), NCI-TCGA Cosmic COSV5447, REVEL 0.86, CADD 28.90, Variant assessed as somatic; moderate impact.
- Q198* (p.Gln198Ter), NCI-TCGA Cosmic COSV5447, Variant assessed as somatic; high impact.
- H202N (p.His202Asn), gnomAD rs79423190
- H202Y (p.His202Tyr), gnomAD rs79423190, REVEL 0.40, CADD 27.10
- R204Q (p.Arg204Gln), NCI-TCGA Cosmic COSV5448, REVEL 0.28, CADD 26.60, Variant assessed as somatic; moderate impact.
- E207D (p.Glu207Asp), TOPMed rs1352488004
- E207G (p.Glu207Gly), gnomAD rs1314711107, REVEL 0.43, CADD 24.80
- R211* (p.Arg211Ter), NCI-TCGA Cosmic COSV1001, CADD 34.00, Variant assessed as somatic; high impact.
- R211G (p.Arg211Gly), gnomAD rs1472271060, REVEL 0.19, CADD 23.80
- R217I (p.Arg217Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V220M (p.Val220Met), TOPMed rs1045943728
- T222I (p.Thr222Ile), gnomAD rs1163092596, REVEL 0.53, CADD 28.30
- T222P (p.Thr222Pro), Ensembl rs1966192831, REVEL 0.56, CADD 27.70
- R226C (p.Arg226Cys), rs1461190074, NCI-TCGA Cosmic COSV5447, gnomAD rs1461190074, REVEL 0.70, CADD 32.00, Variant assessed as somatic; moderate impact.
- R226H (p.Arg226His), gnomAD rs1419045650, REVEL 0.67, CADD 27.50
- L227F (p.Leu227Phe), ESP rs142925902, ExAC rs142925902, gnomAD rs142925902, REVEL 0.67, CADD 27.90
- S228T (p.Ser228Thr), 1000Genomes rs201996601
- G232S (p.Gly232Ser), Ensembl rs1966192359
- G232V (p.Gly232Val), TOPMed rs1966192307
- N234Y (p.Asn234Tyr), Ensembl rs2143008451
- E236K (p.Glu236Lys), NCI-TCGA Cosmic COSV5447, Variant assessed as somatic; moderate impact.
- R237C (p.Arg237Cys), TOPMed rs1186642885, gnomAD rs1186642885, REVEL 0.18, CADD 23.90
- R237H (p.Arg237His), gnomAD rs1422601979, REVEL 0.17, CADD 23.30
- K239T (p.Lys239Thr), gnomAD rs1966191977, REVEL 0.41, CADD 22.80
- Q240E (p.Gln240Glu), NCI-TCGA Cosmic COSV5447, Variant assessed as somatic; moderate impact.
- Q240L (p.Gln240Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- I241M (p.Ile241Met), rs192783364, ClinGen CA280216049, ClinVar RCV000577548, UniProt VAR 066656, AlphaMissense 0.07, MetaLR 0.08, not provided, Parkinson disease 17
- I241V (p.Ile241Val), TOPMed rs1398722917, REVEL 0.06, CADD 16.60, Uncertain significance, Parkinson disease 17
- G245S (p.Gly245Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V250A (p.Val250Ala), TOPMed rs1480205519, gnomAD rs1480205519, REVEL 0.49, CADD 22.90
- V250I (p.Val250Ile), ESP rs375809380, ExAC rs375809380, TOPMed rs375809380, gnomAD rs375809380, REVEL 0.14, CADD 21.50
- N252S (p.Asn252Ser), rs1966167510, ClinGen CA395811776, ClinVar RCV003640675, TOPMed rs1966167510, REVEL 0.13, CADD 18.20, Uncertain significance, Parkinson disease 17
- A256S (p.Ala256Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A258G (p.Ala258Gly), TOPMed rs1966167323
- E260* (p.Glu260Ter), NCI-TCGA Cosmic COSV5447, Variant assessed as somatic; high impact.
- M263I (p.Met263Ile), gnomAD rs1344390220, REVEL 0.38, CADD 28.10
- I266V (p.Ile266Val), ExAC rs773110975, gnomAD rs773110975, REVEL 0.21, CADD 21.80
- I267T (p.Ile267Thr), Ensembl rs1596720944
- Q268E (p.Gln268Glu), Ensembl rs2143008236
- F270C (p.Phe270Cys), ExAC rs761821222, gnomAD rs761821222, REVEL 0.87, CADD 30.00
- P271L (p.Pro271Leu), NCI-TCGA TCGA novel, REVEL 0.65, CADD 29.20, Variant assessed as somatic; high impact.
- Q277R (p.Gln277Arg), ExAC rs760891909, gnomAD rs760891909, REVEL 0.33, CADD 22.30
- N280Y (p.Asn280Tyr), NCI-TCGA Cosmic COSV5447, Variant assessed as somatic; moderate impact.
- P281A (p.Pro281Ala), ExAC rs772459263, gnomAD rs772459263, REVEL 0.27, CADD 22.10
- F282L (p.Phe282Leu), gnomAD rs1256665544, REVEL 0.35, CADD 23.40
- R284Q (p.Arg284Gln), rs771276024, ClinGen CA8036966, ClinVar RCV000286070, ClinVar RCV005894464, REVEL 0.12, CADD 23.20, Uncertain significance, Parkinson disease 17
- R284W (p.Arg284Trp), rs779434158, ClinGen CA8036967, ClinVar RCV004482809, ExAC rs779434158, REVEL 0.33, CADD 31.00, Uncertain significance, Inborn genetic diseases
- L289V (p.Leu289Val), ExAC rs778203456, gnomAD rs778203456, REVEL 0.35, CADD 25.40
- H290Y (p.His290Tyr), ExAC rs754487190, gnomAD rs754487190, REVEL 0.46, CADD 24.40
- Q291E (p.Gln291Glu), NCI-TCGA Cosmic COSV5448, Variant assessed as somatic; moderate impact.
- N292S (p.Asn292Ser), ExAC rs751107774, gnomAD rs751107774, REVEL 0.12, CADD 20.80
- V293G (p.Val293Gly), TOPMed rs1484336774, REVEL 0.72, CADD 28.10
- V295L (p.Val295Leu), ExAC rs779641969, gnomAD rs779641969, Uncertain significance
- V295M (p.Val295Met), rs779641969, ClinGen CA395810809, ClinVar RCV003826438, ExAC rs779641969, REVEL 0.55, CADD 24.20, Uncertain significance, Parkinson disease 17
- I298T (p.Ile298Thr), rs2143008108, ClinGen CA395810785, ClinVar RCV002052343, Ensembl rs2143008108, AlphaMissense 0.91, MetaLR 0.31, Uncertain significance, not provided
- I298V (p.Ile298Val), rs758068523, NCI-TCGA Cosmic COSV1001, ExAC rs758068523, gnomAD rs758068523, REVEL 0.19, CADD 22.40, Variant assessed as somatic; moderate impact.
- A301T (p.Ala301Thr), TOPMed rs1966156294, gnomAD rs1966156294, REVEL 0.23, CADD 24.60
- I303T (p.Ile303Thr), TOPMed rs1966156247
- R305K (p.Arg305Lys), ESP rs371218680, ExAC rs371218680, gnomAD rs371218680
- R305S (p.Arg305Ser), gnomAD rs77133510, REVEL 0.74, CADD 27.90
- L306F (p.Leu306Phe), ExAC rs756137934, gnomAD rs756137934, REVEL 0.48, CADD 25.30
Public VPS35 analysis runs
- VPS35 analysis run — VPS35 (846 variants) — completed 2026-08-18